Lenalidomid Teva

Lenalidomide, the active ingredient in Lenalidomid Teva, is an immunomodulatory drug presented as an oral tablet for oral use. It is indicated for the treatment of certain hematologic malignancies, including multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma in adult patients.

GNH USA supplies Lenalidomid Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Lenalidomid Teva is an immunomodulatory agent used in the management of specific blood cancers.

- Multiple myeloma: helps control disease progression and improve survival. - Myelodysplastic syndromes: reduces transfusion dependence and delays transformation to acute leukemia. - Mantle cell lymphoma: contributes to tumor reduction and prolongs remission.

Lenalidomid Teva may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Fatigue: persistent tiredness. - Nausea: upset stomach, sometimes with vomiting. - Diarrhoea: loose stools. - Constipation: difficulty passing stool. - Rash: mild skin irritation. - Low blood counts: mild neutropenia or anaemia.

Serious or Rare Side Effects: - Deep vein thrombosis or pulmonary embolism. - Severe neutropenia or leukopenia. - Hepatotoxicity: elevated liver enzymes. - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Second primary malignancies. - Severe allergic reactions: anaphylaxis.

Before initiating therapy, clinicians should assess patient risk factors and monitor appropriately.

- Blood count monitoring: perform complete blood counts regularly. - Thromboembolic risk: evaluate and consider prophylactic anticoagulation when indicated. - Pregnancy avoidance: prescribe effective contraception; drug is contraindicated in pregnancy. - Renal/hepatic function: adjust therapy based on organ function assessments. - Vaccination caution: avoid live vaccines during treatment. - Store at room temperature: keep in the original container, protect from moisture and light.

Lenalidomid Teva can interact with several medication classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce drug exposure. - Anticoagulants (e.g., warfarin): increased risk of bleeding or thrombosis. - Live vaccines: heightened risk of infection.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase plasma levels. - NSAIDs: may augment thrombotic risk. - Digoxin: potential for altered serum concentrations. - Other immunomodulatory agents: additive myelosuppression risk.